2 player game

2 player game SAN DIEGO, Dec. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zeta Global Holdings Corp. ZETA securities between February 27, 2024 and November 13, 2024, inclusive (the "Class Period"), have until January 21, 2025 to seek appointment as lead plaintiff of the Zeta Global class action lawsuit. Captioned Davoodi v. Zeta Global Holdings Corp. , No. 24-cv-08961 (S.D.N.Y.), the Zeta Global class action lawsuit charges Zeta Global as well as certain of Zeta Global's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Zeta Global class action lawsuit, please provide your information here: https://www.rgrdlaw.com/cases-zeta-global-holdings-corp-class-action-lawsuit-zeta.html You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com . CASE ALLEGATIONS : Zeta Global is a marketing technology company. The Zeta Global class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Zeta Global used two-way contracts to artificially inflate financial results; (ii) Zeta Global engaged in round trip transactions to artificially inflate financial results; (iii) Zeta Global utilized predatory consent farms to collect user data; and (iv) these consent farms have driven almost the entirety of Zeta Global's growth. The Zeta Global class action lawsuit further alleges that on November 13, 2024 Culper Research published a report entitled "Zeta Global Holdings Corp (ZETA): Shams, Scams, and Spam." On this news, the price of Zeta Global's stock fell by more than 37%. THE LEAD PLAINTIFF PROCESS : The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Zeta Global securities during the Class Period to seek appointment as lead plaintiff in the Zeta Global class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Zeta Global class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Zeta Global class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Zeta Global class action lawsuit. ABOUT ROBBINS GELLER : Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: https://www.rgrdlaw.com/services-litigation-securities-fraud.html Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 info@rgrdlaw.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.GameStop Discloses Third Quarter 2024 ResultsMorsa Images Protara Therapeutics ( NASDAQ: TARA ) was able to report positive phase 2 results using its drug TARA-002 to treat high-risk non-muscle invasive bladder cancer [NMIBC] patients. This mid-stage study is known as ADVANCED-2 and used this drug to treat these This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year. Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Netflix's FIFA Women's World Cup deal feels like a page out of the pay-to-play book: RueterVANCOUVER, BC , Dec. 10, 2024 /PRNewswire/ -- (TSX: LUN) (Nasdaq Stockholm: LUMI) Lundin Mining Corporation ("Lundin Mining" or the "Company") is pleased to announce that Lundin Mining's Swedish short-form document prepared in accordance with Article 1.4 da) and Annex IX of Regulation (EU) 2017/1129 (the "Short Form Document") for the proposed offer of new common shares of Lundin Mining (the "Lundin Mining Shares") to holders of Euroclear Sweden AB registered common shares of Filo Corp. ("Filo") in connection with the previously announced arrangement under the Canada Business Corporations Act whereby the Company and BHP Investments Canada Inc. ("BHP" and together with Lundin Mining, the "Purchaser Parties"), a wholly-owned subsidiary of BHP Group Limited will, among other things, acquire all of the issued and outstanding common shares of Filo not already owned by the Purchaser Parties and their respective affiliates (the "Arrangement"), has been filed with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). View PDF The Short Form Document is available on Lundin Mining's website ( www.lundinmining.com ). The completion of the Arrangement and the issuance of the new Lundin Mining Shares to shareholders of Filo remain subject to the satisfaction of customary closing conditions for a transaction of this nature, including, among other things, regulatory approvals and relevant stock exchange approvals. The Arrangement is anticipated to be completed in the first quarter of 2025 (the "Effective Date") subject to the satisfaction or waiver of closing conditions. Trading of the new Lundin Mining Shares on Nasdaq Stockholm is expected to commence as soon as possible following the Arrangement becoming effective on the Effective Date, subject to Nasdaq Stockholm approving the admission to trading of such shares and completion of the Arrangement. About Lundin Mining Lundin Mining is a diversified Canadian base metals mining company with operations or projects in Argentina , Brazil , Chile , Portugal , Sweden and the United States of America , primarily producing copper, zinc, gold and nickel. The information was submitted for publication, through the agency of the contact persons set out below on December 10, 2024 at 1:00 PM PST . Cautionary Statement on Forward-Looking Information Certain of the statements made and information contained herein are "forward-looking information" within the meaning of applicable Canadian securities laws. All statements other than statements of historical facts included in this document constitute forward-looking information, including but not limited to statements regarding the completion of the Arrangement and the expected timing thereof; the satisfaction of the conditions precedent to the Arrangement; the listing of the new Lundin Mining Shares on Nasdaq Stockholm and the timing thereof; and expectations for other economic, business, and/or competitive factors. Words such as "believe", "expect", "anticipate", "contemplate", "target", "plan", "goal", "aim", "intend", "continue", "budget", "estimate", "may", "will", "can", "could", "should", "schedule" and similar expressions identify forward-looking information. Forward-looking information is necessarily based upon various estimates and assumptions including, without limitation, the expectations and beliefs of management, including the Company's ability to achieve goals; the prompt and effective integration of acquisitions, including the completion of the Arrangement; the establishment of the 50/50 joint arrangement with BHP and the realization of synergies and economies of scale in connection therewith; and assumptions related to the factors set forth below. While these factors and assumptions are considered reasonable by Lundin Mining as at the date of this document in light of management's experience and perception of current conditions and expected developments, these statements are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking information and undue reliance should not be placed on such information. Such factors include, but are not limited to, global financial conditions, market volatility and inflation; the ability to consummate the Arrangement; the ability to obtain requisite regulatory approvals and the satisfaction of other remaining conditions to the consummation of the Arrangement on the proposed terms and schedule; the establishment of the 50/50 joint arrangement with BHP and the realization of synergies and economies of scale in connection therewith; the inability to currently control Filo and the ability to satisfy the relevant conditions and complete the Arrangement and establish the 50/50 joint arrangement with BHP on the proposed terms and schedule; risks relating to joint ventures, joint arrangements and operations; the potential impact of the consummation of the Arrangement on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time on the Arrangement. This forward-looking information may be affected by risks and uncertainties in the business of Lundin Mining and Filo and market conditions; and other risks and uncertainties, including but not limited to those described in the "Risks and Uncertainties" section of the Company's MD&A for the three and nine months ended September 30, 2024 and the "Risks and Uncertainties" section of the Company's Annual Information Form for the year ended December 31, 2023 , which are available on SEDAR+ at www.sedarplus.com under the Company's profile. All of the forward-looking information in this document is qualified by these cautionary statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, forecasted or intended and readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking information. Accordingly, there can be no assurance that forward-looking information will prove to be accurate and forward-looking information is not a guarantee of future performance. Readers are advised not to place undue reliance on forward-looking information. The forward-looking information contained herein speaks only as of the date of this document. The Company disclaims any intention or obligation to update or revise forward ‐ looking information or to explain any material difference between such and subsequent actual events, except as required by applicable law. For further information, please contact: Stephen Williams , Vice President, Investor Relations: +1 604 806 3074; Robert Eriksson , Investor Relations Sweden: +46 8 440 54 50SAN ANTONIO, Texas (AP) — Zach Calzada threw for 182 yards and his 17-yard scoring pass to Roy Alexander was the game's only touchdown and Incarnate Word beat Villanova 13-6 on Saturday in the second round of the FCS playoffs. The Cardinals (11-2), who earned their highest seed in program history at No. 6, travel to face third-seeded South Dakota State in the quarterfinals. Brack Peacock kicked a 23-yard field goal to give the Cardinals a 3-0 lead with 8:48 before halftime. Villanova (10-4) tied it on 49-yard field goal by Ethan Gettman almost five minutes later. Late in the third, Gettman gave the Wildcats their lone lead when he kicked a 52-yarder. Calzada connected with Roy early in the fourth and Peacock added insurance in the last stanza with a 35 yarder with 4:14 remaining. Lontrell Turner had 120 yards rushing on 18 carries for Incarnate Word. Connor Watkins threw for 103 yards and an interception for Villanova whose offense was outgained 437-138. The Wildcats hadn't been kept out of the end zone since Nov. 5, 2022 when Towson beat Villanova 27-3. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/) Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgen

Tomorrow’s talent begins their journey at Gwent manufacturing firmNone

Inside Team Trump’s Big Bet On Election Integrity — And How It Paid Off

Florida lawmaker's party switch increases Republican supermajority in the HouseSGX securities turnover value rises 51% in November; volume up 12%BRITS brace themselves for more Baltic weather as a -6C freezing fog hits the north with snow set to fall just before Christmas. Storm Darragh has barely blown over but The Met Office has already issued another slew of yellow weather warnings. Across parts of Scotland a freezing fog will arrive, covering Glasgow , starting today until 11am tomorrow. The warning stated: "Areas of freezing fog will continue to make travel conditions rather difficult overnight and Wednesday morning." Temperatures will reach down to -6C in some areas with light wind also cautioned. This means that public services might be delayed or even cancelled, with slower journey times in general. Read more News Cyclists are more at risk on the roads with the chill exacerbating any icy patches along the tarmac. Slippery roads might also affect cars, motorbikes and any other road vehicle. The yellow warning issues to Glasgow has a medium likelihood and a low impact - meaning if you're in the area you are likely to be affected by fog, but it might not be too extreme. It covers central Glasgow as well as some areas further out including Lanark, Alexandria, Cumbernauld, and parts of Stirling. Most read in The Sun These parts could get frosty and even face some snow over the long nights with "widespread frost under prolonged cloud break" according to the Met Office. Nowhere else in the UK has been issued any weather warning following Storm Darragh but flood warnings remain in place. Brits have also been warned it will "be breezy" in other areas of the UK but by Wednesday it should clear up for most. This comes as the wreckage of storm Darragh continues to shock the country, with two deaths from falling trees on Saturday. The fourth named storm of the season brought strong winds to many parts of the country over the weekend with millions warned to stay indoors. Thousands were left without power and flights, trains, and buses were cancelled for safety reasons. Entertainment fixtures, like football, were also cancelled for both travel and safety reasons. As what will happen over Christmas, the Met Office has said on Wednesday 25 December there will be unsettled conditions. The forecaster warned of frosts and fog, with strong gusts winds and drizzle moving up from the southeast. On Christmas week, the Met Office revealed some Brits can expect the white stuff to fall. Read More on The US Sun The forecaster's long range weather forecast from December 22 to January 5 reads: "Some sleet and snow is also likely at times, especially on high ground in the north." Unfortunately most are more likely to get a wet Christmas than a white one. According to the Met Office Driving safely in fog Foggy conditions can make it difficult to see the road ahead, be prepared for this by following these simple steps: Make sure you know where your fog light switch is before you set off. Keep a bigger distance between you and the car in front. Be prepared for a sudden bank of fog or drifting, patchy fog. Check your mirrors and slow down before entering fog. Use fog lights when visibility drops below 100 metres, which is roughly the length of a football pitch. Don't use full beam as fog reflects the light back. Once the fog has lifted switch off your fog lights. How does fog affect flights and ferry crossings Fog can affect schedules for flights and ferry crossings. People cope better with delays or cancellations when they follow some small and easy steps: Check the weather for your departure location regularly. Make sure you check your phone for messages from your airline or ferry company. You can also check their websites and social media platforms for additional updates. Arrive on time at the airport or ferry terminal, even if delays are expected. Pack your hand luggage with delays in mind. For example, some people may need to pack extra prescription medicine or baby food. How to avoid transport delays Give yourself the best chance of avoiding delays on your journey by following this two-step checklist: CHECK: check bus and train timetables and the road conditions AMEND: amend your travel plans

The standard Lorem Ipsum passage, used since the 1500s "Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" To keep reading, please log in to your account, create a free account, or simply fill out the form below.

Syria's new transitional prime minister on Tuesday said it was time for "stability and calm" in the country, two days after longtime president Bashar al-Assad was toppled by rebels in a lightning offensive. The rebels appointed Mohammad al-Bashir as the transitional head of government to run the country until March 1, a statement said. US Secretary of State Antony Blinken urged all nations to support an "inclusive" political process in Syria, saying the United States would eventually recognise a government if it meets such standards. "Now it is time for this people to enjoy stability and calm," Bashir told Qatar's Al Jazeera television in his first interview since being appointed. A senior official told US broadcaster NBC that Assad was in Moscow, after he fled Syria as an Islamist-led rebel alliance swept into Damascus on Sunday, ending five decades of brutal rule by his clan. Abu Mohammed al-Jolani, the Islamist leader who headed the rebel offensive, had announced talks on a transfer of power and vowed to pursue former senior officials responsible for torture and war crimes. Jolani on Tuesday sought to allay fears over how Syria would be ruled, telling British broadcaster Sky News that Syria was "exhausted" by war and would not be heading back into one. "Syria will be rebuilt... The country is moving towards development and reconstruction. It's going towards stability," he said. "People are exhausted from war. So the country isn't ready for another one and it's not going to get into another one." His group, Hayat Tahrir al-Sham, is rooted in Syria's Al-Qaeda branch and is proscribed by many Western governments as a terrorist organisation, though it has sought to moderate its image. Blinken said the future government of Syria should be "credible, inclusive and non-sectarian". Laying out US priorities, Blinken said the new government must "uphold clear commitments to fully respect the rights of minorities" and allow the flow of humanitarian assistance. The United States wanted the next government to "prevent Syria from being used as a base for terrorism", he added. Although they no longer hold any territory in Syria, the jihadists of the Islamic State group remain active. The Syrian Observatory for Human Rights war monitor said IS fighters killed 54 government troops after capturing them as they fled across the vast Syrian desert. The UN envoy for Syria said the groups that forced Assad to flee must transform their "good messages" into actions on the ground. "They have been sending messages of unity, of inclusiveness," Geir Pedersen said. "What we need not to see is... that this is not followed up in practice in the days and the weeks ahead of us," he added. EU foreign policy chief Kaja Kallas warned of the risks of sectarian violence and a resurgence of extremism. "We must avoid a repeat of the horrific scenarios in Iraq, Libya and Afghanistan." Syria's nearly 14-year civil war killed 500,000 people and forced half the country to flee their homes, millions of them finding refuge abroad. Jolani, who now uses his real name Ahmed al-Sharaa, vowed: "We will not hesitate to hold accountable the criminals, murderers, security and army officers involved in torturing the Syrian people." More from this section The fall of Assad has sparked a frantic search by families of the tens of thousands of people held in his security services' jails and detention centres. As they advanced towards Damascus, the rebels released thousands of detainees, but many more remain missing. Syria's White Helmet rescuers on Tuesday called on Russia to pressure Assad into providing maps of secret jails and lists of detainees as they race against time to release prisoners. A large crowd gathered Monday outside Saydnaya jail, synonymous with the worst atrocities of Assad's rule, to search for relatives, many of whom had spent years in captivity, AFP correspondents reported. "I'm looking for my brother, who has been missing since 2013. We've looked everywhere for him, we think he's here, in Saydnaya," said 52-year-old Umm Walid. Crowds of freed prisoners wandered the streets of Damascus, many maimed by torture, weakened by illness and emaciated by hunger. The United Nations said whoever ended up in power in Syria must hold Assad and his lieutenants to account. UN investigators who for years have been gathering evidence of horrific crimes called Assad's ouster a "game-changer" because they will now be able to access "the crime scene". While Syrians were celebrating Assad's ouster, the country now faces enormous uncertainty, and it is unclear whether the dreams of democracy so many sacrificed their lives for will be realised. Further complicating prospects, the Israeli military said it had conducted hundreds of strikes on Syria over the past two days. Pedersen, the UN special envoy for Syria, called on Israel to stop. "We are continuing to see Israeli movements and bombardments into Syrian territory. This needs to stop," he said. But Israeli Prime Minister Benjamin Netanyahu warned Syria's new rulers that he would respond "forcefully" if they allow "Iran to re-establish itself in Syria, or permits the transfer of Iranian weapons or any other weapons to Hezbollah". Lebanon's Hezbollah meanwhile said it hoped that Syria's new rulers would "take a firm stand against Israeli occupation, while preventing foreign interference in its affairs". The Britain-based Observatory said Israeli strikes had "destroyed the most important military sites in Syria". The monitor said the strikes targeted weapons depots, naval vessels and a research centre that Western governments suspected of having links to chemical weapons production. Israel, which borders Syria, also sent troops into the UN-patrolled buffer zone east of the Israeli-annexed Golan Heights. Israel backer the United States said the incursion must be "temporary", after the United Nations said Israel was violating the 1974 armistice. The Israeli defence minister said the military had orders to "establish a sterile defence zone free of weapons and terrorist threats in southern Syria, without a permanent Israeli presence." bur-ser/jsa/

NonePublished 4:55 pm Friday, November 22, 2024 By Daily Herald Photo provided Photo provided Photo provided Photo provided By Tim Ruzek John Hulet heard his calling in 1933 while throwing horseshoes near the Cedar River in Horace Austin State Park. A man standing on the iron bridge that once extended North Main Street over the Cedar saw a 3-year-old boy fall into the river upstream. The man yelled to the 18-year-old Hulet, who ran to the river and pulled the boy out of about 5 feet of water. On the shore, Hulet gave CPR or “artificial respiration” to the boy – Roland Zook – for a few minutes until Zook showed signs of life, the Austin Daily Herald wrote Sept. 18, 1933. “(Hulet) then carried the boy to the Zook home, where he was worked on for about an hour,” the Herald wrote, adding that Zook was placed between warm blankets because he was blue from the river’s cold water. By the next day, however, Zook had “completely recovered from the narrow escape from drowning.” Zook went on to live until age 88, passing away in 2019 in northern California. After moving with his family to California, Zook served as a U.S. Marine in the Korean War; married his wife in Los Angeles; and raised two children while working as an iron worker and insurance agent. Nearly 30 years after Zook was saved, Hulet —now an Austin police officer since 1945 — heard another scream for help from the Cedar River at Austin Mill Pond. Hulet was fishing in Austin Mill Pond’s southwest corner on the Sunday afternoon of June 23, 1963. Four boys — ages 8 to 10 — had formed a chain while swimming in the river when one broke loose and went underwater where there was a steep drop. Hulet dove into the river, which was deep enough to go over his head, and pulled the boy out. Hulet told the Herald the boy appeared uninjured but was so scared he ran home before he could be identified. A woman at the scene verified the rescue. Hulet the hero In the early 1930s, Hulet and Zook lived a block apart along Lansing Avenue — today’s First Drive Northwest — with their backyards overlooking Austin Mill Pond and the state park. Their homes later were removed for building Austin’s first YMCA and the Red Cedar Inn (today’s Cedars of Austin complex). About 4:30 p.m. on Sept. 15, 1933, the 3-year-old Zook joined a 4-year-old girl in walking to the state park near the Rayman boat house on a sharp river bend that curved around the property that today hosts Bremer Bank. Zook and the girl were playing near the river when something got Zook’s attention. “The Zook boy thought he saw a fish in the water and reached down to seize it,” the Herald wrote. “He lost his balance and tumbled in. The water was about 5 feet deep.” A man never identified was standing on the Charles Fox Bridge (installed just two years earlier and removed in 1961). He saw the boy fall in the river and he called out to Hulet, who graduated four months earlier from Austin High School. “At this time of the year, there are very few people near the state park along the Cedar River,” the Herald wrote. “The only persons at the park at the time the boy fell in the water were the man on the bridge and Hulet.” Hulet’s “quick action” in pulling the boy from the river and use of CPR were credited by Zook’s father with saving his son’s life. The father said he wished he also could find the unknown man on the bridge to thank him. Life of service At the time of his death in 1989 at age 74, Hulet was described in a Herald obituary as an avid fisherman who “spent many pleasant hours on the shores of many a river and lake.” “A well-known and well-respected man in the community, he always had a ‘word of greeting’ to anyone who crossed his path,” the obituary stated April 2, 1989. “He was a kind and loving husband, a caring and dependable father, a protective grandpa and a faithful friend.” Hulet worked for 12 years at the Hormel plant after high school. During that time, Hulet also played on many amateur sports teams for baseball, basketball, bowling and even hockey – a rarity in the 1930s in southern Minnesota. Known as the “big Austin third baseman,” Hulet was named in 1937 as the “most valuable player” at the Minnesota State Amateur Baseball Tournament, receiving the Governor’s Trophy. In 1945, Hulet left Hormel to start a 24-year career as an Austin police patrol officer. The father of five was highlighted for his police work numerous times in the Herald. Hulet then chose to work as a custodian for Austin Public Schools until 1977, when he retired for good.

Here's How Much $1000 Invested In Ameriprise Finl 15 Years Ago Would Be Worth Today

Overhauls of 'heritage brands' raise the question: How important are our products to our identities?Players must be assigned female at birth or have transitioned to female before going through male puberty to compete in LPGA tournaments or the eight USGA championships for females under new gender policies published Wednesday. The policies, which begin in 2025, follow more than a year of study involving medicine, science, sport physiology and gender policy law. The updated policies would rule out eligibility for Hailey Davidson, who missed qualifying for the U.S. Women's Open this year by one shot and came up short in LPGA Q-school. Davidson, who turned 32 on Tuesday, began hormone treatments when she was in her early 20s in 2015 and in 2021 underwent gender-affirming surgery, which was required under the LPGA's previous gender policy. She had won this year on a Florida mini-tour called NXXT Golf until the circuit announced in March that players had to be assigned female at birth. “Can't say I didn't see this coming,” Davidson wrote Wednesday on an Instagram story. “Banned from the Epson and the LPGA. All the silence and people wanting to stay ‘neutral’ thanks for absolutely nothing. This happened because of all your silence.” LPGA commissioner Mollie Marcoux Samaan, who is resigning in January, said the new gender policy "is reflective of an extensive, science-based and inclusive approach." By making it to the second stage of Q-school, Davidson would have had very limited status on the Epson Tour, the pathway to the LPGA. The LPGA and USGA say their policies were geared toward being inclusive of gender identities and expression while striving for equity in competition. The LPGA said its working group of experts advised that the effects of male puberty allowed for competitive advantages in golf compared with players who had not gone through puberty. “Our policy is reflective of an extensive, science-based and inclusive approach,” said LPGA Commissioner Mollie Marcoux Samaan, who announced Monday that she is resigning in January. "The policy represents our continued commitment to ensuring that all feel welcome within our organization, while preserving the fairness and competitive equity of our elite competitions.” Mike Whan, the former LPGA commissioner and now CEO of the USGA, said it developed the updated policy independently and later discovered it was similar to those used by swimming, track and field, and other sports. United States Golf Association CEO Mike Whan said the new policy will prevent anyone from having "a competitive advantage based on their gender." “It starts with competitive fairness as the North star,” Whan said in a telephone interview. “We tried not to get into politics, or state by state or any of that stuff. We just simply said, ‘Where would somebody — at least medically today — where do we believe somebody would have a competitive advantage in the field?’ And we needed to draw a line. “We needed to be able to walk into any women's event and say with confidence that nobody here has a competitive advantage based on their gender. And this policy delivers that.” The “Competitive Fairness Gender Policy” for the USGA takes effect for the 2025 championship season that starts with the U.S. Women's Amateur Four-Ball on May 10-14. Qualifying began late this year, though there were no transgender players who took part. “Will that change in the years to come as medicine changes? Probably,” Whan said. “But I think today this stacks up.” The LPGA “Gender Policy for Competition Eligibility” would apply to the LPGA Tour, Epson Tour, Ladies European Tour and qualifying for the tours. Players assigned male at birth must prove they have not experienced any part of puberty beyond the first stage or after age 12, whichever comes first, and then meet limitation standards for testosterone levels. The LPGA begins its 75th season on Jan. 30 with the Tournament of Champions in Orlando, Florida. Buffalo Bills quarterback Josh Allen, foreground right, dives toward the end zone to score past San Francisco 49ers defensive end Robert Beal Jr. (51) and linebacker Dee Winters during the second half of an NFL football game in Orchard Park, N.Y., Sunday, Dec. 1, 2024. (AP Photo/Adrian Kraus) South Carolina guard Maddy McDaniel (1) drives to the basket against UCLA forward Janiah Barker (0) and center Lauren Betts (51) during the first half of an NCAA college basketball game, Sunday, Nov. 24, 2024, in Los Angeles. (AP Photo/Eric Thayer) Mari Fukada of Japan falls as she competes in the women's Snowboard Big Air qualifying round during the FIS Snowboard & Freeski World Cup 2024 at the Shougang Park in Beijing, Saturday, Nov. 30, 2024. (AP Photo/Andy Wong) LSU punter Peyton Todd (38) kneels in prayer before an NCAA college football game against Oklahoma in Baton Rouge, La., Saturday, Nov. 30, 2024. LSU won 37-17. (AP Photo/Gerald Herbert) South Africa's captain Temba Bavuma misses a catch during the fourth day of the first Test cricket match between South Africa and Sri Lanka, at Kingsmead stadium in Durban, South Africa, Saturday, Nov. 30, 2024. (AP Photo/Themba Hadebe) Philadelphia Eagles running back Saquon Barkley, left, is hit by Baltimore Ravens cornerback Marlon Humphrey, center, as Eagles wide receiver Parris Campbell (80) looks on during a touchdown run by Barkley in the second half of an NFL football game, Sunday, Dec. 1, 2024, in Baltimore. (AP Photo/Stephanie Scarbrough) Los Angeles Kings left wing Warren Foegele, left, trips San Jose Sharks center Macklin Celebrini, center, during the third period of an NHL hockey game Monday, Nov. 25, 2024, in San Jose, Calif. (AP Photo/Godofredo A. Vásquez) Olympiacos' Francisco Ortega, right, challenges for the ball with FCSB's David Miculescu during the Europa League league phase soccer match between FCSB and Olympiacos at the National Arena stadium, in Bucharest, Romania, Thursday, Nov. 28, 2024. (AP Photo/Andreea Alexandru) New York Islanders left wing Anders Lee (27), center, fight for the puck with Boston Bruins defensemen Parker Wotherspoon (29), left, and Brandon Carlo (25), right during the second period of an NHL hockey game, Wednesday, Nov. 27, 2024, in Elmont, N.Y. (AP Photo/Julia Demaree Nikhinson) Jiyai Shin of Korea watches her shot on the 10th hole during the final round of the Australian Open golf championship at the Kingston Heath Golf Club in Melbourne, Australia, Sunday, Dec. 1, 2024. (AP Photo/Asanka Brendon Ratnayake) Mathilde Gremaud of Switzerland competes in the women's Freeski Big Air qualifying round during the FIS Snowboard & Freeski World Cup 2024 at the Shougang Park in Beijing, Friday, Nov. 29, 2024. (AP Photo/Andy Wong) Lara Gut-Behrami, of Switzerland, competes during a women's World Cup giant slalom skiing race, Saturday, Nov. 30, 2024, in Killington, Vt. (AP Photo/Robert F. Bukaty) New York Islanders goaltender Ilya Sorokin cools off during first period of an NHL hockey game against the Boston Bruins, Wednesday, Nov. 27, 2024, in Elmont, N.Y. (AP Photo/Julia Demaree Nikhinson) Las Vegas Raiders tight end Brock Bowers (89) tries to leap over Kansas City Chiefs cornerback Joshua Williams (2) during the first half of an NFL football game in Kansas City, Mo., Friday, Nov. 29, 2024. (AP Photo/Ed Zurga) Luiz Henrique of Brazil's Botafogo, right. is fouled by goalkeeper Everson of Brazil's Atletico Mineiro inside the penalty area during a Copa Libertadores final soccer match at Monumental stadium in Buenos Aires, Argentina, Saturday, Nov. 30, 2024. (AP Photo/Natacha Pisarenko) England's Alessia Russo, left, and United States' Naomi Girma challenge for the ball during the International friendly women soccer match between England and United States at Wembley stadium in London, Saturday, Nov. 30, 2024. (AP Photo/Kirsty Wigglesworth) Melanie Meillard, center, of Switzerland, competes during the second run in a women's World Cup slalom skiing race, Sunday, Dec. 1, 2024, in Killington, Vt. (AP Photo/Robert F. Bukaty) Houston Rockets guard Jalen Green goes up for a dunk during the second half of an Emirates NBA cup basketball game against the Minnesota Timberwolves, Tuesday, Nov. 26, 2024, in Minneapolis. (AP Photo/Abbie Parr) Brazil's Botafogo soccer fans react during the Copa Libertadores title match against Atletico Mineiro in Argentina, during a watch party at Nilton Santos Stadium, in Rio de Janeiro, Saturday, Nov. 30, 2024. (AP Photo/Bruna Prado) Seattle Kraken fans react after a goal by center Matty Beniers against the San Jose Sharks was disallowed due to goaltender interference during the third period of an NHL hockey game Saturday, Nov. 30, 2024, in Seattle. The Sharks won 4-2. (AP Photo/Lindsey Wasson) Brazil's Amanda Gutierres, second right, is congratulated by teammate Yasmin, right, after scoring her team's first goal during a soccer international between Brazil and Australia in Brisbane, Australia, Thursday, Nov. 28, 2024. (AP Photo/Pat Hoelscher) Gold medalists Team Netherlands competes in the Team Sprint Women race of the ISU World Cup Speed Skating Beijing 2024 held at the National Speed Skating Oval in Beijing, Sunday, Dec. 1, 2024. (AP Photo/Ng Han Guan) Minnesota Vikings running back Aaron Jones (33) reaches for an incomplete pass ahead of Arizona Cardinals linebacker Mack Wilson Sr. (2) during the second half of an NFL football game Sunday, Dec. 1, 2024, in Minneapolis. (AP Photo/Abbie Parr) Sent weekly directly to your inbox!

Penguin That Swam From Antarctica To Australia Is Returned To Sea After Exhausting Trip

Ambuja Cements shares 1.23% as NiftyWhen Katja Vogt considers a Jaguar, she pictures a British-made car purring confidently along the Italian coastline — a vision of familiarity that conveys "that dreaming, longing feeling we all love." She's not sure what to think about Jaguar now after the 89-year-old company announced a radical rebranding that featured loud colors and androgynous people — but no cars. Jaguar, the company says, will now be JaGUar. It will produce only electric vehicles beginning in 2026. Bad attention is good attention, Jaguar execs would appear to believe. The car brand has prompted mockery online for posting a glitzy ad without a single car in it. Say goodbye to British racing green, Cotswold Blue and black. Its colors are henceforth electric pink, red and yellow, according to a video that sparked backlash online. Its mission statement: "Create exuberance. Live vivid. Delete ordinary. Break moulds." "Intrigued?" @Jaguar posted on social media. "Weird and unsettled" is more like it, Vogt wrote on Instagram. "Especially now, with the world feeling so dystopian," the Cyprus-based brand designer wrote, "a heritage brand like Jaguar should be conveying feelings of safety, stability, and maybe a hint of rebellion — the kind that shakes things up in a good way, not in a way that unsettles." Jaguar was one of several iconic companies that announced significant rebrandings in recent weeks, upending a series of commercial — and cultural — landmarks by which many modern human beings sort one another, carve out identities and recognize the world around them. Campbell's, the 155-year-old American icon that artist Andy Warhol immortalized in pop culture decades ago, is ready for a new, soupless name. Comcast's corporate reorganization means there will soon be two television networks with "NBC" in their name — CNBC and MSNBC — that will no longer have any corporate connection to NBC News, a U.S. legacy news outlet. CNBC One could even argue the United States itself is rebranding with the election of former President Donald Trump and Republican majorities in the House and Senate. Unlike Trump's first election in 2016, he won the popular vote in what many called a national referendum on American identity. Are we, then, the sum total of our consumer decisions — what we buy, where we travel and whom we elect? Certainly, it's a question for those privileged enough to be able to afford such choices. Volumes of research in the art and science of branding — from "brandr," an old Norse word for burning symbols into the hides of livestock — say those factors do contribute to the modern sense of identity. So rebranding, especially of heritage names, can be a deeply felt affront to consumers. "It can feel like the brand is turning its back on everything that it stood for — and therefore it feels like it's turning its back on us, the people who subscribe to that idea or ideology," said Ali Marmaduke, strategy director with the Amsterdam-based Brand Potential. He said cultural tension — polarization — is surging over politics, wars in Russia and the Mideast, the environment, public health and more, creating what Marmaduke said is known as a "polycrisis": the idea that there are several massive crises converging that feel scary and complex. Campbell's soups "People are understandably freaked out by that," he said. "So we are looking for something that will help us navigate this changing, threatening world that we face." Trump's "Make America Great Again" qualifies. So did President Joe Biden's "Build Back Better" slogan. Campbell's soup itself — "Mmm Mmm Good" — isn't going anywhere, CEO Mark Clouse said. The company's new name, Campbell's Co., will reflect "the full breadth of our portfolio," which includes brands like Prego pasta sauce and Goldfish crackers. None of the recent activity around heritage brands sparked a backlash as ferocious as Jaguar's. The company stood as a pillar of tradition-loving British identity since World War II. The famous "leaper" cat Jaguar logo is pictured in 2019 at the Auto show in Paris, France. Jaguar said its approach to the rebrand was rooted in the philosophy of its founder, Sir William Lyons, to "copy nothing." What it's calling "the new Jaguar" will overhaul everything from the font of its name to the positioning of it's famous "leaper" cat. "Exuberant modernism" will "define all aspects of the new Jaguar world," according to the news release. The approach is thought to be aimed at selling fewer cars at a six-figure price point to a more diverse customer base. The reaction ranged from bewilderment to hostility. Memes sprouted up likening the video to the Teletubbies, a Benetton ad and — perhaps predictably — a bow to "woke" culture as the blowback intersected with politics. Get the latest local business news delivered FREE to your inbox weekly.LaGrange Academy Middle School girls basketball team is off to hot start

PITTSBURGH (AP) — Pittsburgh Steelers wide receiver George Pickens was a full participant in practice on Monday, opening the door for him to return from a three-game absence on Wednesday when Pittsburgh hosts the Kansas City Chiefs. Pickens hasn't played since tweaking his hamstring earlier this month. The Steelers (10-5) have struggled to generate much in their passing game with their leading receiver watching from the sideline in sweatpants. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get any of our free email newsletters — news headlines, obituaries, sports, and more.

AG Labrador: Three Pocatello men arrested for child enticement during undercover operation

Amherst Town Council highlightsMono Next Plc (MONO) is considering legal action against the Stock Exchange of Thailand (SET), saying the bourse's announcement on Dec 3 about irregular trading of the digital TV operator's shares caused unnecessary panic among investors and affected its share price. Navamin Prasopnet, acting chief executive of the media and content firm, clarified that the changes in the trading conditions of its ordinary shares are based on external factors and circumstances beyond the company's control. MONO considers the SET's actions to be excessive and lacking appropriate consideration of their impact on both investors and the company, he said. The company is considering exercising its legal rights regarding actions that caused damage to the company and its shareholders in order to protect their interests, Mr Navamin reported via the SET website yesterday. The SET on Tuesday announced that MONO is subject to Level 1 trading control measures from Nov 27 to Dec 17, 2024, as the bourse identified certain groups of individuals who may reasonably be believed to have acted in concert, engaging in substantial daily transactions of the shares. Mr Navamin said the warning caused unnecessary panic and disproportionate harm, adversely affecting the company's stock price and investor confidence in the company and its securities, without sufficient legal justification. "Should the SET possess clear evidence indicating violations of applicable laws, it is obligated to report such incidents to the Securities and Exchange Commission for further legal action," he said. Such warnings require a higher degree of caution because they may have a widespread impact on investors, said Mr Navamin. According to the SET's statement, MONO's share price and trading value soared daily for four business days until Dec 2, rising 31.5% since the trading control measures took effect, without any new material information during the period. The high turnover may indicate higher speculation, as the daily turnover percentage increased continuously from an average of 0.75% before the measures to 3.04%, noted the bourse. The SET identified a group of people trading roughly 15% of the total trading value each day, contributing to the upward price movement. The bourse said if the trading conditions of MONO securities are still abnormal without supporting fundamental factors, the stock will be upgraded from Level 1 control measures to Level 2, in accordance with market surveillance protocols. Level 1 trading control measures prohibit credit limit calculation and requires 100% cash payment for trading of such shares. Level 2 measures comprise the prohibition of net settlement, exclusion from credit limit calculation, a cash balance requirement and use of the auction-only trade method.